双氢青蒿素逆转人肺腺癌细胞多药耐药作用研究  

Inhibition of growth on the human lung adenocarcinoma cell line A549 and A549/CDDP in vitro by dihydroartemisinin in combination with cisplatin.

作　　者：陈卫强[1] 戚好文[1] 吴昌归[1] 李志奎[1] 柏长青[1] 刘颖格[1] 

机构地区：[1]第四军医大学西京医院呼吸内科,陕西西安710032

出　　处：《现代肿瘤医学》2006年第3期284-286,共3页Journal of Modern Oncology

基　　金：西安市科技局基金资助(SF-200223)

摘　　要：目的观察双氢青蒿素和顺铂在体外对A549及A549/CDDP细胞的作用,分析双氢青蒿素抗肺癌和逆转耐药效果。方法采用细胞计数法绘制亲代A549细胞和A549/CDDP细胞生长曲线,细胞增殖及增殖抑制实验采用MTT检测法:A549/CDDP细胞分为顺铂单药作用组,联合作用组(100nM双氢青蒿素加顺铂,320nM双氢青蒿素加顺铂),序贯治疗组(100nM双氢青蒿素预处理),用MTT检测法分析计算IC50值进行比较。结果顺铂对人肺腺癌A549细胞和A549/CDDP细胞IC50值分别为0.270μg/ml和5.703μg/ml,耐药倍数为21.12。对A549/CDDP细胞,联合治疗100nM双氢青蒿素组顺铂IC50值为2.225μg/ml(逆转倍数2.56),320nM双氢青蒿素组顺铂IC50值0.464μg/ml(逆转倍数12.29)。对A549/CDDP细胞,序贯治疗组顺铂IC50为2.523μg/ml(逆转倍数2.26)。结论联合用药和序贯治疗均可逆转A549/CDDP细胞对顺铂的耐药。Objective To observe the inhibiting effect of dihydroartemisinin and cisplatin on human lung adenocarcinoma cell line A549 and A549/CDDP ,and determine the effect of resistance reversion of dihydroartemisinin in vitro. Methods Inhibition of proliferation in vitro was measured by MTT assay. The human lung carcinoma cell line A549/CDDP were assigned to one of the four groups：cisplatin group; combined group 1 （ 100nM dihydroartemisinin and cisplatin） ; combined group 2 （ 320nM dihydroartemisinin and cisplatin ） ; pre - treated with dihydroartemisinin group. Results After 96h of treatment, the IC50 for cisplatin of A549 and A549/CDDP cell number was 0.270μg/ml and 5. 703 μg/ml. The drug resistance multiple was 21.12. In the dihydroartemisinin plus cisplatin group, the IC50 of cisplatin was 2.225μg/ml in the low dose group and 0.464μg,/ml in the high dose dihydroartemisinin group. The reversion multiple was 2.56 and 12.29. The IC50 （cisplatin） of pre - treated by 100nM dihydroartemisinin on A549/ CDDP were 2. 523μg/ml. Conclusion Dihydroartemisinin can reverse cisplatin resistance of A549/CDDP in vitro.

关 键 词：双氢青蒿素 肺癌 顺铂 耐药 

分 类 号：R734.2[医药卫生—肿瘤]